Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
4 evidence topics · 4 sources
Phase 3 regimen: 1-week run-in dose followed by the target dose, with no dose reduction
“AD109 dose was aroxybutynin 2.5 mg/atomoxetine 37.5 mg for week 1 and aroxybutynin 2.5 mg/atomoxetine 75 mg for the remaining weeks (dose reductions not permitted).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose reduction is not permitted, and dosing is discontinued if the participant experiences intolerance to the assigned study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement on dose adjustment for tolerability in clinical practice
Atomoxetine dose relative to the maximum recommended ADHD dose
Higher aroxybutynin dose (5/75 mg) in dose finding (MARIPOSA)
“It is unclear why we did not see improvement with the higher dose of AD109, although higher rates of daytime symptoms such as dry mouth, urinary hesitation, constipation, and somnolence were reported with the higher dose of aroxybutynin, suggesting more tolerability issues with the AD109 5/75 mg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote